BridgeBio Pharma, Inc.
corporate_fare Company Profile
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 48 items for BBIO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for BBIO spans 10-Q, 8-K, SCHEDULE 13D/A, 424B7.
Recent high-impact activity:
- BridgeBio Q3: Revenue Triples to $353M, Loss Narrows to $60M, Cash Reaches $1.5B
- BridgeBio Q3 Revenue Triples to $353.2M; Three PDUFA Dates in Seven Months
- Q3 Revenue Triples to $353M as Attruby Climbs; Three PDUFA Dates in Seven Months
- FDA Grants Priority Review to BridgeBio's Oral Infigratinib for Achondroplasia
- Acoramidis Cuts Hospitalizations 27% vs Tafamidis in Largest EHR Study
Financial Snapshot
Short Interest & Short Volume
7.06 days to coverFINRA reported short interest of 20,846,164 shares in BBIO as of the October 30, 2026 settlement, a 4.2% increase from the prior period — about 7.1 days to cover at its recent average daily volume. On November 20, 2026, 37.9% of BBIO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for BBIO, detected from its recent SEC filings · based on capital-structure filings through 2026-08-14.
Secured $933.9 Million in Preferred Equity · Convertible at Significant Premium
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →